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Drug overdose deaths increased for the 11th consecutive year causing 38,329 deaths in
the United States in 2010, with nearly 60 percent of the those deaths (22,134) involving
pharmaceutical drugs. Opioid analgesics, such as oxycodone, hydrocodone, and methadone,
were involved in about 3 of every 4 pharmaceutical overdose deaths (16,651), confirming the
predominant role opioid analgesics play in drug overdose deaths according to an analysis from
the CDC released in February 2013.1
This trend continues to grow, despite opioid harm reduction strategies such as medication
formulations that decrease methods of abuse, education initiatives (such as www.AwareRX.org,
founded in Minnesota), public medication take-back events, proper prescribing initiatives, and
state-run Prescription Drug Monitoring Programs. When these efforts fail to prevent an
overdose, a proven avenue to reduce morbidity and mortality is the use of naloxone, a pure
opioid antagonist. Injectable naloxone has been available in the US for more than 40 years and
is a standard rescue medication carried by emergency medical services (EMS). Some EMS
programs have further developed a system to administer the injectable formulation intranasally
via a marketed atomizer/nebulizer device, thereby decreasing concerns of transferring blood
borne pathogens.2
Rescue strategies are needed that reach beyond emergency response systems, thus
becoming more accessible to the general public. Although programs of distribution continue to
expand across the country, nineteen (76.0%) of the 25 states with 2008 drug overdose death rates
higher than the median and nine (69.2%) of the 13 states in the highest quartile did not have a
community-based opioid overdose prevention program that distributed naloxone.3 Proper
education and training is essential as the potential benefits of naloxone are temporary;

consequently, all users are instructed to call for emergency assistance as part of standard
protocols. As highlighted in a recent article by Bailey et. al., community-based pharmacy
practitioners have worked toward overcoming logistic and cultural barriers to make naloxone
distribution for overdose a standard and acceptable practice.4
Despite the increased recognition to improve access, some safety and ethical concerns
have been raised in previous debates on expanded use of the medication. Health professionals
have noted fatalities may result, especially if used by untrained people, and perhaps naloxone use
may increase avoidance of contacting EMS.4 - 6 Though due to naloxone’s short-half life, it is
critical to receive additional medical services after the antidote is administered as further
“reversal” may be warranted.6 Another major obstacle has been that many states do not include
naloxone as part “Good Samaritan” regulations protecting against legal implications when
tending to persons in need of emergency aid.4
In April of 2012, the FDA, the Center for Drug Evaluation and Research, the Office of the
Assistant Secretary for Health, National Institutes of Drug Abuse, and the Centers for Disease
Control and Prevention (CDC) sponsored a public discussion on the potential value of making
naloxone more widely available to reduce the incidence of opioid overdose fatalities. The
majority of individuals participating in the program were in support of an over-the-counter
(OTC) approval of naloxone. However, several steps must occur to facilitate an OTC switch. An
intranasal (or auto – injector) formulation would require bioequivalence studies since this current
delivery form is off – label, as well as data to support safety, chemistry, and manufacturing. An
OTC switch would also require usage studies to ensure patients or caregivers can understand
directions and determine if product use is appropriate for them.5

Pros and cons exist for an OTC naloxone. Impact from an OTC version will greatly increase
the availability of naloxone; therefore, possibly saving thousands of lives if used correctly.
Conversely, misuse of the product could result in deaths through lack of patient education and
failure to contact EMS. Pharmacists play a critical role in the appropriate use of nonprescription
medications in self-care and this may be an optimal product to be considered with the
Nonprescription Safe Use Regulatory Expansion (NSURE) Initiative requiring a consult with the
pharmacist prior to sale.9
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